PubMed Health⌕ Search

PubMed · 9423128

[Dynamic cardiomyoplasty: current status and future perspective].

Abstract

Dynamic Cardiomyoplasty is a new approach to manage patients with heart failure. The phase I study shows that the muscle stimulator and electrodes function as designed and that the operation is done without any impairment of the patient's motor function. The results of the phase II study has been made public. The hemodynamic effects on patients with dilated cardiomyoplasty have been reported to be excellent. The assisting mechanism of dynamic cardiomyoplasty is based on the conformational change of the wrapped muscle with the ability to restore its optimal length and tension. In the chronic postoperative stage, the muscle seems to form a layer outside the epicardium. This change is important for the myocardinal sparing and girdling effects which are related to the wall stress of the heart. The hypothesis that the wrapped muscle becomes another layer of the heart can explain these effects. Increasing the wall thickness of the left ventricle reduces the wall stress (myocardinal sparing effect) according to Laplace's law. Even if the wrapped muscle is not transformed or stimulated (adynamic cardiomyoplasty), the wall stress is reduced after conformation, and the dilatation of the heart may be protected (girdling effect). The systolic augmentation is shown as the increase of cardiac output, ejection fraction, and blood velocity of the ascending aorta and ejection time. The dynamic cardiomyoplasty might effect the remodelling of the impaired heart and delay its progressive dilatation. When the efficacy of dynamic cardiomyoplasty is proven by the phase III study, which has been going on in the centers of North and South Americas, it will be useful as a bridge to heart transplantation, or as one of the surgical treatment modalities for advanced heart failure.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R C Chiu, Y Misawa, T Hasegawa, K Fuse. 1994. [Dynamic cardiomyoplasty: current status and future perspective].. https://pubmed.ncbi.nlm.nih.gov/9423128/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

The bidirectional genetic causality between immunocyte phenotypes and dilated cardiomyopathy: A bidirectional Mendelian randomization study.

The association between immunocyte phenotypes and dilated cardiomyopathy (DCM) has been explored, however the exact pathogenesis of the relationship between immune cells and DCM is unclear. This bidirectional two-sample Mendelian randomization (MR) research aims to further validate the causal link between 731 immunocyte phenotypes and DCM. Summary statistics from a genome-wide association study data of individuals with European ancestry were utilized, including 1444 DCM cases and 353,937 controls, as well as 3757 European adults for the 731 immunocyte phenotypes. Causal effects were estimated using inverse variance weighted, MR-Egger regression, weight median estimator, weighted mode, and simple mode. Sensitivity analysis was conducted to confirm data robustness and feasibility. Based on the inverse variance weighted findings, 14 immunocyte phenotypes were risk factors for DCM (P&#x2005;<&#x2005;.05, odds ratio [OR]&#x2005;>&#x2005;1), while 15 immunocyte phenotypes exhibited a protective effect on DCM (P&#x2005;<&#x2005;.05, OR&#x2005;<&#x2005;1). The results of reverse MR analysis suggested evidence that DCM occurrence might elevate the levels of 17 immunocyte phenotypes (P&#x2005;<&#x2005;.05, OR&#x2005;>&#x2005;1) and decrease the levels of 9 immunocyte phenotypes (P&#x2005;<&#x2005;.05, OR&#x2005;<&#x2005;1). Our research indicated that CD28 on secreting regulatory T cell could mitigate the occurrence of DCM, and reciprocally, the progression of DCM could reduce the level of CD28 on secreting regulatory T cell. This study confirmed the bidirectional genetic predictive relationship between immunocyte phenotypes and DCM, underscoring the complex interplay between DCM and the immune system.

Cardiomyopathy, Dilated↗

Neuroblastoma presenting with dilated cardiomyopathy.

We report an infant with neuroblastoma who presented with dilated cardiomyopathy. A 3-month-old girl presented with dilated cardiomyopathy diagnosed as stage III neuroblastoma. Since total resection was impossible, chemotherapy was started. Cardiomyopathy was normalized by improvement of neuroblastoma. The prompt improvement of cardiac function following treatment of neuroblastoma suggested that cardiomyopathy in this patient was caused by the increase in catecholamines secreted by neuroblastoma and that reduction in catecholamines by treatment of neuroblastoma led to improvement in the cardiomyopathy.

Cardiomyopathy, Dilated↗